Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease-Reference-Cited by-同舟云学术

Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease

Published:2020-09-01 Issue:5 Volume:202 Page:660-671
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Singh Dave¹,Bafadhel Mona²^ORCID,Brightling Christopher E.³,Sciurba Frank C.⁴,Curtis Jeffrey L.⁵⁶^ORCID,Martinez Fernando J.⁷,Pasquale Cara B.⁸,Merrill Debora D.⁹,Metzdorf Norbert¹⁰,Petruzzelli Stefano¹¹,Tal-Singer Ruth⁹,Compton Christopher¹²,Rennard Stephen¹³¹⁴,Martin Ubaldo J.¹⁵

Affiliation:

1. Division of Infection, Immunity, and Respiratory Medicine, University of Manchester, Manchester University National Health Service Hospital Trust, Manchester, United Kingdom

2. Respiratory Medicine Unit, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

3. Institute for Lung Health, National Institute for Health Research Leicester Biomedical Research Centre, Department of Respiratory and Infection Sciences, University of Leicester, Leicester, United Kingdom

4. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

5. Pulmonary and Critical Care Medicine, VA Ann Arbor Healthcare System, Ann Arbor, Michigan

6. Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan

7. Pulmonary and Critical Care Medicine, Weill Cornell Medical College, New York, New York

8. COPD Patient-Powered Research Network, COPD Foundation, Washington, DC

9. COPD Biomarkers Qualification Consortium, COPD Foundation, Miami, Florida

10. Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany

11. Global Clinical Development, Chiesi Farmaceutici, Parma, Italy

12. Global Medical Affairs, Speciality and Primary Care, GlaxoSmithKline, Middlesex, United Kingdom

13. Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom

14. University of Nebraska Medical Center, Omaha, Nebraska; and

15. Research and Development, AstraZeneca, Gaithersburg, Maryland

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Reference79 articles.

1. Precision medicine in COPD: where are we and where do we need to go?

2. FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) resource. Silver Spring, MD: Food and Drug Administration (US); 2016.

3. European Medicines Agency. Qualification of novel methodologies for medicine development: guidance to applicants. Amsterdam, the Netherlands: European Medicines Agency; 2014.

4. Treatable traits: toward precision medicine of chronic airway diseases

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The genetic etiology of body fluids on chronic obstructive airways disease;Respiratory Research;2024-01-19

2. Phenotypes, Etiotypes, and Endotypes of Exacerbations of Chronic Obstructive Pulmonary Disease;American Journal of Respiratory and Critical Care Medicine;2023-11-15

3. Optimizing inhaled corticosteroid use in patients with chronic obstructive pulmonary disease: assessing blood eosinophils, neutrophil–to–lymphocyte ratio, and mortality outcomes in US adults;Frontiers in Immunology;2023-11-15

4. Inhaled Maintenance Therapy in the Follow-Up of COPD in Outpatient Respiratory Clinics. Factors Related to Inhaled Corticosteroid Use. EPOCONSUL 2021 Audit;Archivos de Bronconeumología;2023-11

5. How inhaled corticosteroids target inflammation in COPD;European Respiratory Review;2023-10-18